According to market analysis, the global Cell Line Development Market is predicted to expand at a compound annual growth rate (CAGR) of 12.9% during the forecast period (2024-2031).
The demand for cell line development (CLD) processes is increasing due to the expansion of the biopharmaceutical sector, leading to the growth of the cell line development market. The majority of biopharma businesses use cells as an expression host for the synthesis of recombinant monoclonal antibodies and proteins. The availability of enhanced technologies to manufacture novel cell lines and an increase in demand for monoclonal antibodies and cancer therapies are projected to drive market expansion in coming years. Moreover, the growing acceptance of novel biopharmaceutical medications, as well as a growth in the prevalence of chronic diseases, is driving demand for biopharmaceutical products. Innovative product offerings will arise from the increased use of cutting-edge technology, such as bio-recombinant proteins, in the treatment of numerous chronic diseases. The adoption of CLD is increasing the efficiency of safety and effectiveness of biopharmaceutical products, boosting the growth of the market. This is because this increasing efficiency is improving their potential to cure diseases that were earlier incurable.
Get a Free Sample Research Report:
https://www.skyquestt.com/sample-request/cell-line-development-market
Segmental Analysis
By Product - Reagents and media, Equipment, Incubators, Centrifuges, Bioreactors, Storage equipment, Microscopes, Accessories and consumables
By Source - Mammalian cell line, non-mammalian cell line, Insects, Amphibians
By Type of Cell Line - Recombinant cell lines, Hybridomas, Continuous cell lines, Primary cell lines
By Application - Bioproduction, Drug discovery, Toxicity testing, Tissue engineering, Research
By Region - North America, Europe, Asia Pacific, Latin America, The Middle East & Africa
Emergence of Biologics to Offer Better Targeted Treatment Options
The rising demand for biologics, like monoclonal antibodies, vaccines, and biosimilars, is boosting the growth of cell line development market. Biologics provide targeted treatment options for several diseases. This is encouraging the pharmaceutical companies to focus on increasing the advancement and efficiency of production systems. Biosimilars are cost-efficient alternatives, further fueling the necessity for quick and strong cell line development. With the expansion of biopharmaceutical sector, organizations are investing heavily in research to enhance cell lines, improve production, and reduce timespan. This transformation highlights the growing dependency on biologics because it is a type of primary treatment model in medical systems globally.
Ask for Customization:
https://www.skyquestt.com/speak-with-analyst/cell-line-development-market
Key Players Operating in the Cell Line Development Market
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Lonza
• Fujifilm Holdings Corporation
• JSR Corporation
• Selexis SA
• Horizon Discovery Ltd.
• Rentschler Biopharma SE
• Boehringer Ingelheim International GmbH
• Sartorius AG
• AGC Biologics
• Cytiva
• Cyagen
• Catalent
• Eurofins Scientific
Implemetation of Single-Use Technologies to Reduce Risk of Contamination
Single-use bioreactor systems are changing the cell line development procedure. These systems minimize the risk of contamination, raises operational flexibility, and enable quicker improvement in production sets. Furthermore, biopharmaceutical manufacturers are adopting single-use technologies because they are cost-efficient and can adapt in small- and large-scale production houses. With the growing demand for personalized medicine grows, single-use systems are becoming vital in guaranteeing fast production of customized therapies. The implementation of this technology is growing rapidly, as it resolves many challenges like scale-up flexibility, space-saving, and quicker market access.
- In September 2023, Lineage Cell Therapeutics made announcement about the development of engineered hypoimmune pluripotent cell lines. This solution will help in the treatment of neurological indications.
- In June 2023, Matica Bio launched MatiMax HEK293 and HEK293T cell lines. It will help to advance the development of cell and gene therapies.
- In November 2022, Lonza launched an innovative new capsule solution for enteric (intestinal) drug delivery. With Capsugel EnprotectTM it will become easier to make drug products.
View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/cell-line-development-market
This Market has the Following Segments
Product
- Reagents and media
- Equipment
- Incubators
- Centrifuges
Source
- Mammalian cell line
- Non-mammalian cell line
- Insects
- Amphibians
Type of Cell Line
- Recombinant cell lines
- Hybridomas
- Continuous cell lines
- Primary cell lines
Application
- Bioproduction
- Drug discovery
- Toxicity testing
- Tissue engineering
Increasing Focus on Automation and AI in Cell Line Screening to Improve Accuracy
Automation and artificial intelligence (AI) are playing a crucial role in enhancing the speed and accuracy of cell line screening and development. Depending of the preferred traits AI-based systems are utilized for analyzing massive datasets, forecast cell line behavior, and improve cell line selection. Furthermore, automation and robotics are smoothening tedious and repetitive activities like media preparation, cell culture monitoring, and scaling. This is helping in reducing human error and increasing production. These technologies are changing the market by minimizing development time, increasing efficiency, and decreasing operational expenses. These factors are positively influencing the growth of the cell line development market.
Visit Our Website: https://www.skyquestt.com/
Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/cell-line-development-market
